Preparation errors are far likelier to name a compounded version
Of 81,078 reports on semaglutide and its relatives, the 707 involving compounded products far more often mentioned preparation errors and contamination. Odds are not risks.
What the study found
Preparation errors appear 49 times as often in compounded reports
Reporting odds are not risks, and this is the clearest case of that difference. Of 81,078 reports on semaglutide and its relatives to the US adverse event system, the 707 involving compounded products were far likelier to mention preparation errors, contamination and manufacturing faults.
The caveat · Most pharmacies need not report
Spontaneous reports have no denominator, so none of these ratios is a risk to a patient and none supports saying the products caused anything. Only 707 of the 81,078 reports involved compounded products, and some ratios rest on a handful of events, which is why the preparation-error interval runs from 12.63 to 189.6. State-licensed pharmacies mostly do not have to report at all, which biases the comparison in a direction the analysis cannot correct.
What we don't know
Compounded semaglutide was named less often in reports of dosing errors, against the regulator's own warning about overdoses. Uneven reporting is likelier than safer products, but nothing in the data can settle it.